Ionis Pharmaceuticals (NASDAQ:IONS) announced that the U.S. Food and Drug Administration approved ZANVASTRO (zilganersen) for pediatric and adult patients with Alexander disease, making it the first disease-modifying treatment approved for the condition.
Milestone Pharmaceuticals (NASDAQ:MIST) received regulatory approval from China's National Medical Products Administration for its etripamil nasal spray, triggering a $2 million milestone payment.
Pharvaris (NASDAQ:PHVS) presented translational, nonclinical, and clinical data on its oral bradykinin B2 receptor antagonist deucrictibant at the Bradykinin Symposium 2026 in Berlin.
Aptevo Therapeutics (NASDAQ:APVO) reported clinical results showing that 13 of 14 evaluable frontline TP53-mutated acute myeloid leukemia (AML) patients treated with its mipletamig triplet regimen achieved clinical benefit.
CollPlant Biotechnologies (NASDAQ:CLGN) completed its acquisition of Israeli deep-tech company LightSolver, expanding into high-performance computing and photonics while continuing its existing regenerative medicine operations.
AbbVie (NYSE:ABBV) completed its acquisition of Apogee Therapeutics (NASDAQ:APGE), paying $135.11 per share in cash for an equity value of approximately $10.9 billion as of September 3, 2026.
American Healthcare REIT (NYSE:AHR) acquired eight Class A senior housing communities for approximately $696 million, expanding its presence in East Coast senior housing markets.
HUTCHMED (NASDAQ:HCM) signed an exclusive development and license agreement with a GSK subsidiary for HMPL-A830, a KRAS-EGFR Antibody-Targeted Therapy Conjugate, covering worldwide rights outside Mainland China, Hong Kong, Macau, and Taiwan.
United Therapeutics Corporation (NASDAQ:UTHR) announced that the FDA accepted its supplemental New Drug Application for nebulized Tyvaso (treprostinil) Inhalation Solution as a potential treatment for idiopathic pulmonary fibrosis (IPF).
uniQure (NASDAQ:QURE) submitted a Biologics License Application to the U.S. FDA and a Marketing Authorisation Application to the U.K. MHRA for ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for Huntington’s disease.
Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline Phase 2a results for TEV ‘408, its investigational anti-IL-15 monoclonal antibody for adults with celiac disease following a gluten-free diet.
Aurora Cannabis (NASDAQ:ACB) recommended that shareholders reject Curaleaf Holdings’ unsolicited hostile takeover bid, advising investors not to tender their shares or withdraw any previously tendered shares.
